Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A11 | Q9UPY5 | 6/20 | 0.54 |
| ▸ | VDAC2 | P45880 | 1/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.44 |
| ▸ | CCR1 | P32246 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.40 |
| ▸ | JUN | P05412 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27256092 | 0.97 | SLC7A11 (0.51) | SLC7A11VDAC2HRH3KCNH2CCR1 | |
| SCHEMBL13633731 | 0.89 | SLC7A11 (0.64) | SLC7A11VDAC2HRH3KCNH2CCR1 | |
| SCHEMBL27256095 | 0.89 | VDAC2 (0.42) | SLC7A11VDAC2KMT2ASMN1; SMN2CXCR3 | |
| SCHEMBL13633677 | 0.89 | SLC7A11 (0.59) | SLC7A11VDAC2HRH3KCNH2CCR1 | |
| SCHEMBL13633720 | 0.87 | CACNA2D1 (0.58) | SLC7A11VDAC2CCR1KMT2A | |
| SCHEMBL13633721 | 0.85 | SLC7A11 (0.68) | SLC7A11VDAC2HRH3KCNH2KMT2A | |
| SCHEMBL13633614 | 0.84 | VDAC2 (0.57) | SLC7A11VDAC2HRH3KCNH2KMT2A | |
| SCHEMBL12829874 | 0.83 | SMN1; SMN2 (0.43) | HRH3KCNH2KMT2ASMN1; SMN2CXCR3 | |
| SCHEMBL27256099 | 0.82 | VDAC2 (0.55) | SLC7A11VDAC2HRH3KCNH2KMT2A | |
| SCHEMBL13633579 | 0.82 | CXCR3 (0.42) | KMT2ACXCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240207270-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING LIPID METABOLISM | WAVEBREAK INC (US) | 2024-06-27 | — | — | US | disclosed |
| US-8518959-B2 | Quinoxaline derivatives as antitumor agents | PROLEXYS PHARMACEUTICALS, INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-8518959-B2 | Quinoxaline derivatives as antitumor agents | PROLEXYS PHARMACEUTICALS, INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-7615554-B2 | Erastin and erastin binding proteins, and uses thereof | PROLEXYS PHARMACEUTICALS, INC. (US) | 2009-11-10 | — | — | US | disclosed |
| US-7615554-B2 | Erastin and erastin binding proteins, and uses thereof | PROLEXYS PHARMACEUTICALS, INC. (US) | 2009-11-10 | — | — | US | disclosed |
| US-20090214465-A1 | Quinoxaline Derivatives as Antitumor Agents | PROLEXYS PHARMACEUTICALS, INC. (US) | 2009-08-27 | — | — | US | disclosed |
| US-20090214465-A1 | Quinoxaline Derivatives as Antitumor Agents | PROLEXYS PHARMACEUTICALS, INC. (US) | 2009-08-27 | — | — | US | disclosed |
| US-20070161644-A1 | Erastin analogs and uses thereof | STOCKWELL BRENT R | 2007-07-12 | — | — | US | disclosed |
| US-20070161644-A1 | Erastin analogs and uses thereof | STOCKWELL BRENT R | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161644-A1 | Erastin analogs and uses thereof | ERAP2, ERAP1, ERAL1 | SLC7A11 1250/4885VDAC2 3980/4885HRH3 3021/4885 |
| US-20240207270-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING LIPID METABOLISM | CPT2, PC, SREBF2 | SLC7A11 906/4885VDAC2 553/4885HRH3 4720/4885 |
| US-20090214465-A1 | Quinoxaline Derivatives as Antitumor Agents | VDAC3, VDAC2, VDAC1 | SLC7A11 565/4885VDAC2 2/4885HRH3 2827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.